Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InMed Pharmaceuticals ( (INM) ) has issued an update.
InMed Pharmaceuticals has published a study revealing the potential of cannabinol (CBN) as an anti-inflammatory agent for skin diseases. The research highlights how CBN modulates the endocannabinoid system, showing promise for treating conditions like psoriasis and atopic dermatitis. This development could pave the way for therapeutic and cosmetic applications, underscoring CBN’s role in regulating skin inflammation and offering protective benefits.
Learn more about INM stock on TipRanks’ Stock Analysis page.